

Two reviewers recommended immediate acceptance of our minireview, while additionally noting the manuscript was “well written.” The third reviewer concurred, but suggested “minor revision,” for “some phrases” – which were unspecified. To address the third reviewer’s gentle criticism, we re-examined the entire manuscript, and made the following three minor edits, for improved clarity:

- *Successful interventions to reduce the incidence and complications associated with all NMSCs, SCCs, in particular, as well as AKs, would represent a significant advance in the management of KTRs. Indeed, despite heroic “conversion” protocols, i.e., from calcineurin inhibitor-based to mechanistic/mammalian target of rapamycin [mTOR] inhibitor-based (primarily, sirolimus) immunosuppressive regimens, KTRs with a predilection for NMSCs, especially SCCs, continue to develop new malignant skin lesions at grossly elevated rates [7,8]*. The second sentence was edited to, *Despite heroic “conversion” protocols from calcineurin inhibitor-based to mechanistic/mammalian target of rapamycin [mTOR] inhibitor-based (primarily, sirolimus) immunosuppressive regimens, KTRs with a predilection for NMSCs, especially SCCs, continue to develop new malignant skin lesions at grossly elevated rates [7,8]*
- *Their findings, verbatim, were described thusly<sup>[14]</sup>*; was edited to, *The following is a verbatim description of their findings [14]*:
- *Thus NAM’s putative in vivo role as an inhibitor of sirtuins, and sirtuin-catalyzed “pro-oncogenic” de-acetylation, and hyper-phosphorylation reactions [16-19] warrants investigation, as another pathophysiological correlate, in NAM-treated patients.* We removed the awkward “Thus” at the beginning of the sentence. *NAM’s putative in vivo role as an inhibitor of sirtuins, and sirtuin-catalyzed “pro-oncogenic” de-acetylation, and hyper-phosphorylation reactions [16-19] warrants investigation, as another pathophysiological correlate, in NAM-treated patients.*

We hope these changes suffice and render the manuscript publishable in its current form. We have also added the “Core tip” text, included an accompanying mp3 file with these same “Core tip” statements, and formatted the revised minireview per the other editorial requirements.

Sincerely,

Andrew Bostom, MD, MS